About LAV Asset Management
LAV Asset Management is a venture capital firm founded in 2008. It is primarily based out of Huangpu, China. As of Apr 2026, LAV Asset Management is an active investor, having invested in 29 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series C round of Pulnovomed Overall, LAV Asset Management portfolio has seen 9 IPOs and 3 acquisitions including key companies like Alector, In Silico and Innovent Bio. A lot of funds co-invest with LAV Asset Management, with names like Qiming Venture Partners sharing a substantial percentage of its portfolio. LAV Asset Management has team of 4 people including 4 partners.Key Metrics
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
LAV Asset Management's List of Top Investments
LAV Asset Management has a portfolio of 29 companies. Their most notable investments are in Singleron and Ansun BioPharma.Their portfolio spans across United States, China, Canada and 3 more locations. They have invested in Life Sciences, High Tech, HealthTech and 2 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by LAV Asset Management:
1. Alector
Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders. The drug candidates include AL001 for dementia, AL101 for neurology, AL002, AL003, AL014 for Alzheimer's, and AL008 for oncology. The company has developed antibody drugs that engage key disease-altering and genetically validated neuro-immune targets.
Key facts about Alector
- Founded Year: 2013
- Location: San Francisco (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $215M
- Employee Count: 139 as on Jun 30, 2026
- Investors: Foresite Capital, Amgen Business Development and 20 Others
- Latest Funding Round: Series E, Jul 25, 2018, $*****
- Highlight: Public
2. In Silico
AI-enabled bioinformatics platform for drug discovery and biomarker development. The company provides solutions and services such as custom drug discovery engines, biomarker discovery, and aging research tools to academia, pharmaceutical, and cosmetics companies. Also, it has developed a product PHARMA.AI which includes modules for drug discovery such as PandaOmics, Chemistry42, and InClinico.
Key facts about In Silico
- Founded Year: 2014
- Location: Cambridge (United States)
- Annual Revenue: $1 - $1M as on Jul 18, 2017
- Stage: Public
- Total Funding till date: $510M
- Employee Count: 284 as on Jun 30, 2026
- Investors: BHR, F-Prime Capital and 36 Others
- Latest Funding Round: Series E, Jan 07, 2025, $*****
- Highlight: Public
3. Innovent Bio
Developer of antibody therapeutics for multiple diseases. It offers monoclonal and bispecific antibodies to treat several cancers such as non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, colorectal cancer, and lung cancer. Also, has antibody binding to TNF-α preventing it from activating TNF receptors, and will be used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, and other autoimmune diseases.
Key facts about Innovent Bio
- Founded Year: 2011
- Location: Suzhou (China)
- Stage: Public
- Total Funding till date: $535M
- Employee Count: 856 as on Jun 30, 2026
- Investors: F-Prime Capital, Sanofi and 24 Others
- Latest Funding Round: Post IPO, Aug 08, 2022, $*****
- Highlight: Public
Developing MasterKey therapies to defeat cancer resistance and improve patient lives. The company is focused on creating innovative oral therapies designed to address broad, genetically defined patient populations, overcome resistance mechanisms, and minimize wild-type mediated toxicities. Their MasterKey approach aims to expand treatment options by offering one solution for many mutations, particularly in non-small cell lung cancer (NSCLC) and glioblastoma (GBM). They support patient advocacy groups and are committed to providing people living with cancer the opportunity to experience longer, healthier, and more active lives. The company leverages advancements in liquid biopsies and next-generation sequencing to target oncogenic alterations with limited existing therapies. Their therapies are designed to be brain penetrant to treat CNS disease.
Key facts about Black Diamond Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $207M
- Employee Count: 50 - 199 as on Mar 01, 2026
- Investors: Colt Ventures, RA Capital Management and 19 Others
- Latest Funding Round: Series C, Dec 05, 2019, $*****
- Highlight: Public
5. Structure
Developer of oral small molecule drugs for chronic diseases. It offers GPCR structure-based biologic and peptide drugs for pulmonary hypertension, pulmonary fibrosis, type 2 diabetes, and obesity. It has a structure-based technology platform that combines receptor-binding interactions with the simulation of molecular motion and signal transduction for drug development.
Key facts about Structure
- Founded Year: 2017
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $191M
- Employee Count: 233 as on Jun 30, 2026
- Investors: BVF Partners, F-Prime Capital and 17 Others
- Latest Funding Round: Series B, Aug 01, 2022, $*****
- Highlight: Public
LAV Asset Management's Year-on-Year Investment Trends
LAV Asset Management has invested in 29 companies over the last 10 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 4 investments, while as of Apr 2026, it has made 1 investment in this year. Its most recent first time investment was in Avenzo Therapeutics and most recent follow-on round was in Pulnovomed.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 3 | 1 | 4 |
2024 | 1 | 3 | 4 |
2023 | 2 | 1 | 3 |
2022 | 4 | 4 | 8 |
2021 | 7 | 2 | 9 |
2020 | 1 | 2 | 3 |
2019 | 3 | 3 | 6 |
2018 | 5 | 0 | 5 |
LAV Asset Management's Investments by Stage
LAV Asset Management has made 12 investments in Series A stage with an average round size of $84.5M, 6 investments in Series B stage with an average round size of $70.3M and 3 investments in Series C stage with an average round size of $89.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 12 |
Series B | 6 |
Series C | 3 |
Series D | 3 |
Series E | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
LAV Asset Management's Investments by Sector
LAV Asset Management has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, Enterprise Applications and HealthTech. Notably, it has invested in 24 Enterprise (B2B) companies, 24 Tech companies, 3 Tech hardware companies and at least 2 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 23 |
High Tech | 6 |
Healthcare | 5 |
Enterprise Applications | 2 |
HealthTech | 2 |
Others | 3 |
Note: We have considered here, only first round of investments
LAV Asset Management's Investments by Geography
LAV Asset Management has made most investments in United States (13), followed by China where it has made 10 investments.Country | No. of Investments |
|---|---|
United States | 13 |
China | 10 |
Canada | 1 |
Germany | 1 |
Japan | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
LAV Asset Management's recent investments
LAV Asset Management has made 1 investments in 2026 so far - Pulnovomed.Here are the most recent investments by LAV Asset Management:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 20, 2026 | United States | Series C | 1181 | [+5] | |
Aug 22, 2025 | United States | Series B | 8245 | [+12] | |
Mar 03, 2025 | United States | Series C | 5746 | ||
Mar 02, 2025 | China | Series C | 6577 | ||
Jan 09, 2025 | United Kingdom | Series A | 1984 | [+5] |
IPOs and Publicly Listed companies in LAV Asset Management's Portfolio
9 of LAV Asset Management's portfolio companies have become public. Impact Therapeutics got listed on the Hong Kong Exchanges (HKG), in May 2026 at marketcap of $710M and In Silico got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.72B.Here are LAV Asset Management's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 13, 2026 | Mar 14, 2022 | Series D | 6752 | |
Dec 30, 2025 | Sep 09, 2019 | Series B | 4621 | |
Apr 15, 2025 | May 20, 2021 | Series B | 6707 | |
Jan 26, 2024 | Jun 09, 2021 | Series A | 6183 | |
Feb 03, 2023 | Oct 20, 2021 | Series B | 3963 |
Acquired companies in LAV Asset Management's Portfolio
3 companies from LAV Asset Management's portfolio have been acquired. The most recent acquisition was Terns Pharmaceutical in Mar 2026 by Merck for $*****.Here are LAV Asset Management's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 25, 2026 | Jan 05, 2021 | Series C | 7461 | |
Apr 03, 2024 | Jul 12, 2021 | Series A | 5505 | |
Jan 08, 2024 | Nov 11, 2018 | Series C | 3872 |
Team profile of LAV Asset Management
LAV Asset Management has a team of 4 members including 4 Partners located in China and Singapore. LAV Asset Management's team does not sit on the board of any company as of now.Here is a list of all team members in LAV Asset Management:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Shanghai | - | ||
Partner | Shanghai | - | ||
Partner | Shanghai | - | ||
Partner | Singapore | - |
Co-investors of LAV Asset Management
Over the past 10 years, 282 investors have co-invested in LAV Asset Management's portfolio companies. This includes funds and angels.
- Invested before LAV Asset Management: Lilly Asia Ventures, Orbimed and 65 others have invested in rounds before LAV Asset Management. There are 7 companies where Lilly Asia Ventures has invested before LAV Asset Management and 4 companies where Orbimed has invested before LAV Asset Management.
- Top Co-investors of LAV Asset Management: 109 investors entered a company along with LAV Asset Management. These include investors like Qiming Venture Partners (5 companies).
- Invested after LAV Asset Management: A total of 106 investors have invested in LAV Asset Management's portfolio after their investments. Top Investors include HSG (3 companies), Legend Capital (3 companies) and Lake Bleu Capital (2 companies).
Recent News related to LAV Asset Management
•
Pulnovo Medical Closes $100M Series CFinSMEs•Mar 03, 2025•Pulnovo Medical, Qiming Venture Partners, LAV Asset Management, Orbimed and 1 other
•
Pulnovo Medical Announces Closing of Nearly $100 Million Series C FinancingCNW•Mar 03, 2025•Pulnovomed, Qiming Venture Partners, LAV, Gaorong Capital and 7 others
•
Rona Therapeutics: Nucleic Acid Drug R&D Company Raises $35 MillionPulse 2.0•Jul 19, 2024•RONA Therapeutics, Long River Investment Management, BioTrack Capital, Zhongqi Capital and 3 others
•
TargetingOne completes $14 million in new fundingG-MedTech•Apr 19, 2024•Beijing Xinyi Biotechnology, LAV Asset Management
•
•
Capitalizing on ADC frenzy, ProfoundBio attracts $112M oversubscribed series BFierce Biotech•Feb 12, 2024•Profound Bio, LAV Asset Management, RA Capital Management, Orbimed and 12 others
•
•
Synnovation launches with $102m to advance therapy pipelinePharmaceutical Technology•Jan 25, 2024•Synnovation Therapeutics, LAV Asset Management, Nextech Systems, Sirona Capital and 1 other
•
Comanche Biopharma Secures $75 Million Funding to Develop First Preeclampsia TreatmentBNN•Jan 17, 2024•Comanche, Google Ventures, F-Prime Capital, LAV Asset Management and 4 others
•
Akura Medical Closes $35M Series B FinancingMedical Product Outsourcing•Oct 05, 2023•Akura Medical, The Capital Partnership, AMED Ventures, Unorthodox Ventures and 1 other
